Further Decision Processed by IB
05/03/2025
Back to search
Official data from USPTO
VIFOR PHARMA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Quick snapshot
ST13
US500000079158397Class
3, 5, 35, 39, 41, 42, 45
Filing
79158397
Registration
4948439
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
46
Latest update
05/04/2025
Trademark type
Combined
Nice classes
3, 5, 35, 39, 41, 42, 45
Filing date
09/18/2014
Registration date
05/03/2016
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
11/18/2022
Last transaction
05/04/2025
Responsible office
United States Patent and Trademark Office
Status code
709
Official register
Principal Register
Drawing code
3
Owner type
99
Owner location
CH
Examiner
JUN,WON KYUNG WENDY
Law office
L30
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the wording "VIFOR PHARMA". To the left of the wording is a design element of three horizontal straight lines stacked on top of each other.
Holders and representatives
Holders
Vifor (International) AG (Vifor (International) Ltd.) (Vifor (International) Inc.)
Galenica AG
Representatives
Timothy J. Kelly Fitzpatrick, Cella, Harper & Scinto
Technical classification
Nice Classes
Class 3Class 5Class 35Class 39Class 41Class 42Class 45
Vienna Codes
No Vienna codes available.
Goods and services
Class 3
Soapsperfumeryessential oilscosmeticshair lotions; dentifrices
Class 5
Pharmaceutical preparations for the treatment and prevention of gastro-intestinal disordersurinary tract disorderskidney disorderscapillary hemorrhagesdiabetic retinopathyvenous insufficiency; pharmaceutical preparations for the treatment of gastrointestinal discomforts and gastrointestinal diseasesiron deficiencyiron deficiency anemiadisorders of the central nervous systemophthalmic diseasesdisorders of the respiratory systemheart conditions and other disorders of the cardiovascular systemdiabetes and related diseasesmigraines and other forms of headache; Pharmaceutical products for the treatment of acute or chronic conditions or consequences of or associated with acute or chronic renal diseasesuch as acute renal insufficiencyintrinsic kidney diseaseglomerulonephritistubular disorders and tubulointerstitial diseasesvasculitis of the kidneyvascular injury to the kidneyinfection related kidney disorderskidney neoplasmscongenital and genetic disorderscystic disorders of the kidneysystemic diseases effecting the kidneytoxin damage to the kidney; analgesics; antiviral; anti-infectives; anti-inflammatories; antibiotics; antidepressants; anti-cancer preparations; pharmaceutical preparations for use in organ and tissue transplantation; preparations for the treatment of immunologic diseases; pharmaceutical preparations for dialysis and conditions associated with dialysis; preparations for the treatment of neurodegenerative diseases; Pharmaceutical preparations for treatment of water and electrolyte metabolism disorders and disorders associated with dialysis; medicated lotions for the skin and hair; decongestants and anti-histamines; preparations used as immune system stimulators; scabicides; anti-malarials; cough treatment preparationscough suppressants; preparations for treating coughs and colds; expectorants; anti-leukemic agents; dermatologicals; tissue sealants; vasopressors; pharmaceutical preparationsnondepolarizing skeletal neuromuscular blocking agents; preparations for the treatment of gout; preparations for cessation of smoking; preparations of treatment of Parkinson's disease; vaccines; antiemetics; nasal spray preparations; sanitary preparations for medical uses; parapharmaceutical products for use in dermatology; dietetic foodsdietary supplement; preparations containing unsaturated fatty acidsvitamins and mineralsnutraceuticals for use as a dietary supplement adapted for medical use; food for babies; medical plasters; medical dressings; material for stopping teeth; dental wax; all-purpose disinfectants
Class 35
Import agency services in the field of medicines and pharmaceutical preparations; retail store services featuring pharmaceutical and sanitary preparations; import-export agencies in the fields of medicinespharmaceutical and sanitary preparations
Class 39
Transportstoragedeliverypackaging of goodsmedicinespharmaceutical and sanitary preparations
Class 41
Business training services as relating to pharmaceutical and sanitary products
Class 42
Research and development of medicinespharmaceutical preparations and sanitary care products for others
Class 45
Legal services and legal representation of third parties to the authorities and administration with respect to approval of medicines
Publications
History of USPTO decisions and trademark events.
46 publications found
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
03/21/2025
INNA
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
03/21/2025
XXCR
GENERIC MADRID TRANSACTION CREATED
03/21/2025
INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
07/18/2023
C71T
CANCELLED SECTION 71
11/18/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
11/30/2021
RNWL
INTERNATIONAL REGISTRATION RENEWED
09/13/2018
CHLD
CHANGE OF OWNER RECEIVED FROM IB
10/05/2017
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
02/17/2017
FICS
FINAL DISPOSITION NOTICE SENT TO IB
08/09/2016
FIMP
FINAL DISPOSITION PROCESSED
08/09/2016
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
08/03/2016
R.PR
REGISTERED-PRINCIPAL REGISTER
05/03/2016
PUBO
PUBLISHED FOR OPPOSITION
02/16/2016
GPNX
NOTIFICATION PROCESSED BY IB
02/12/2016
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
01/27/2016
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
01/27/2016
NPUB
NOTICE OF PUBLICATION
01/27/2016
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
01/13/2016
XAEC
EXAMINER'S AMENDMENT ENTERED
01/11/2016
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/08/2016
XAEC
EXAMINER'S AMENDMENT ENTERED
01/08/2016
CNEA
EXAMINERS AMENDMENT MAILED
01/07/2016
CNEA
EXAMINERS AMENDMENT -WRITTEN
01/07/2016
CNEA
EXAMINERS AMENDMENT -WRITTEN
01/06/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/05/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/05/2016
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
01/05/2016
CNFR
FINAL REFUSAL MAILED
07/09/2015
CNFR
FINAL REFUSAL WRITTEN
07/08/2015
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/09/2015
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/09/2015
ALIE
ASSIGNED TO LIE
06/01/2015
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/27/2015
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/23/2015
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/23/2015
RFNT
REFUSAL PROCESSED BY IB
02/06/2015
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
01/13/2015
RFRR
REFUSAL PROCESSED BY MPU
01/13/2015
MAFR
APPLICATION FILING RECEIPT MAILED
01/13/2015
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
01/11/2015
CNRT
NON-FINAL ACTION WRITTEN
01/10/2015
DOCK
ASSIGNED TO EXAMINER
01/08/2015
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/08/2015
SDRC
SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
01/02/2015
Continuous trademark protection
Get notified about every new filing that threatens VIFOR PHARMA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.